The present invention relates to polypeptide variants of porcine trypsin, to nucleic acid molecules encoding these variants, and to host cells comprising such nucleic acid molecules. It also relates to the use of these variants in methods for producing insulin. The invention further relates to the use of these variants as medicaments, as food ingredients, or as feed ingredients and to the use of these variants within a process of manufacturing a food ingredient or a feed ingredient.

A three-dimensional cell culture system that includes a keratin-based hydrogel precursor solution and a cell culture vessel is provided. The precursor solution includes solubilized keratin that has been functionalized to include a crosslinking moiety. The crosslinking moiety exhibits controllable crosslinking, e.g., a photopolymerizable crosslinking moiety. The crosslinking functionality is bonded to the keratin via cysteines following reduction of disulfide bonds of the native keratin. The precursor solution can be combined with cells to form a cell suspension that is disposed on a surface of the cell culture vessel. Alternatively, the cells can be added to a surface of a keratin-based hydrogel that has been formed on a surface of the cell culture vessel. The resulting three-dimensional cell culture system is a biomimetic/biologic, trypsin-degradable cell culture system for expansion of mammalian cells. The expanded cells are expected to possess a morphology similar to the primary cells prior to cultivation.

Disclosed is a composition of a collagen peptide and an elastin peptide, method of producing the same and use thereof. The composition of the present disclosure consists of a collagen peptide and an elastin peptide; the collagen peptide is prepared by enzymatic hydrolysis of a collagen material with pepsin or trypsin, and the elastin peptide is prepared by enzymatic hydrolysis of an elastin material with papain and/or protease Protamex. In the present disclosure, an elastin peptide and a collagen peptide with molecular weight in a specific range are prepared by specific processes, and the composition composed of the two at a suitable ratio can simultaneously and significantly increase the amount of the elastin and collagen in a damaged skin in a small usage amount, and significantly increase the content of hyaluronic acid and hydroxyproline while decrease the content of MMP3, meanwhile, inhibit skin inflammatory factors.

The present invention relates to the novel trypsin ZT isoforms. In particular, the invention relates to the use of trypsin ZT isoforms in medical devices, pharmaceuticals and cosmetics.

Embodiments of the invention provide at least one polymer covalently conjugated to an esterase. The at least one polymer includes a plurality of oxime functional groups.

Embodiments of the invention provide at least one polymer covalently conjugated to an esterase. The at least one polymer includes a plurality of oxime functional groups.

The present invention relates to retroviral vectors, particularly lentiviral vectors, comprising a modified retroviral RNA sequence that is codon-substituted and comprises a reduced number of retroviral open-reading frames, and wherein the retroviral vector is pseudotyped with hemagglutinin-neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, methods of making the same and uses thereof.

The present invention relates to the novel trypsin ZT isoforms. In particular, the invention relates to the use of trypsin ZT isoforms in medical devices, pharmaceuticals and cosmetics.

Disclosed are compositions and formulations comprising enzymes or other biocatalyst that cleave surface-accessible DNA polymers and/or glycoprotein carbohydrate chains at galactose residues in dental calculus, and optionally further include one or more proteolytic enzymes, thereby destroying the structural integrity of the calculus, and allowing it to be readily removed without requiring special treatment by a trained dental professional. Also disclosed are methods for removing dental calculus using the disclosed compositions and formulations.

Provided herein are engineered proteases of the S1A family that are specific for, and capable of, cleaving Factor B. Also provided herein are methods of making and using such engineered proteases. The engineered proteases provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system by reducing complement activation through cleavage and inactivation of Factor B.